Form 4: Ionis Pharmaceuticals Director B. Lynne Parshall Reports Stock Vesting
SEC Form 4
Director B. Lynne Parshall reports the vesting of restricted stock units into 4,677 shares of Ionis Pharmaceuticals common stock.
Summary
- On July 15, 2024, Director B. Lynne Parshall vested 4,677 shares of Ionis Pharmaceuticals common stock from restricted stock units.
- The vesting occurred under a pre-existing Restricted Stock Unit award.
- Following the transaction, Parshall directly owns 87,265 shares of Ionis Pharmaceuticals common stock.
- She also owns 4,079 derivative securities.
Sentiment
Score: 5
Explanation: Neutral sentiment as it is a standard reporting of stock vesting.
Industry Context
This is a routine disclosure related to executive compensation and is typical for publicly traded companies.
Comparison to Industry Standards
- Stock awards are a common component of executive compensation packages in the pharmaceutical industry.
- Companies like Amgen, Biogen, and Gilead Sciences also utilize restricted stock units as part of their compensation strategy to align executive interests with shareholder value.
Stakeholder Impact
- The vesting of shares may have a minor dilutive effect on existing shareholders.
- The transaction aligns the director's interests with those of the shareholders.
Key Dates
| Date | Description |
|---|---|
| 07/15/2024 | Date of transaction: Vesting of Restricted Stock Units and release of shares. |
| 07/16/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.